Conference
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK)
Authors
Lalani A-K; Lalani A; Swaminath A; Pond G; Morgan SC; Azad A; Chu W; Winquist E; Kapoor A; Bonert M
Volume
40
Publisher
American Society of Clinical Oncology
Publication Date
February 16, 2022
DOI
10.1200/JCO.2022.40.6_suppl.TPS398
Conference proceedings
Journal of Clinical Oncology
Issue
6
ISSN
0732-183X